Compare Amer Sports Inc (AS) vs Summit Therapeutics Inc (SMMT) Price & Performance

Amer Sports (AS) trades at $33.47, down 7.46% over 24 hours amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $0.38 surpassing expectations. Revenue growth remains strong at 32% year-over-year in Q1 2026, and the company raised its full-year guidance. Analyst consensus is overwhelmingly bullish with a $58.67 price target, though technical indicators suggest near-term weakness.

The outlook is positive given robust fundamentals and upward earnings revisions, but risks include execution on growth targets and market volatility. The current price presents a potential entry point relative to analyst targets, though investors should monitor the upcoming Q2 2026 earnings report on August 18, 2026, for confirmation of continued momentum.

Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.

Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.